The performance of companies tied to Sildenafil's legacy presents a intricate investment picture . While the initial surge generated substantial returns , generic alternatives have significantly eroded sales . Investing in connected pharmaceutical firms now requires a thorough assessment of proprietary rights , evolving patient shifts , and the pro